Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

972.00 +23.55 (+2.48%)
Streaming Delayed Price Updated: 1:05 PM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Next-Generation GLP-1 Candidate as Obesity Drug Market Expands Rapidly
Via Investor Brand Network
The Next Generation of the GLP-1 Revolution Is Already Underway
Via Investor Brand Network
Eli Lilly & Co. (NYSE:LLY) Passes the "Little Book That Makes You Rich" Growth Screen ↗
Via Chartmill
News headline image
Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders? ↗
The weight loss drug market is on track to reach almost $100 billion. 
Via The Motley Fool
News headline image
The Next Generation of the GLP-1 Revolution Is Already Underway
From BioMedWire
Via GlobeNewswire
News headline image
GoodRx (GDRX) Q1 2026 Earnings Call Transcript ↗
GoodRx (GDRX) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Omada Health (OMDA) Q1 2026 Earnings Transcript ↗
Omada Health (OMDA) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There. ↗
The competition is far behind. 
Via The Motley Fool
News headline image
Omada Health Q1 Earnings Call Highlights ↗
Omada Health (NASDAQ:OMDA) reported what executives described as a “milestone quarter” for the first quarter of 2026, highlighting 42% year-over-year revenue growth, expanding margins, and positive... 
Via MarketBeat
Topics Earnings
News headline image
Eli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked Off ↗
Eli Lilly's next obesity drug, retatrutide, is so popular it's already getting copied. Can Lilly compete with its own drug? 
Via Investor's Business Daily
News headline image
How This Eli Lilly-Tied IPO Stock Fared In Its First Quarter ↗
IPO stock Omada Health easily beat first-quarter sales expectations Thursday, and announced a deal with drug titan Eli Lilly. 
Via Investor's Business Daily
Topics Initial Public Offering
News headline image
Forget Eli Lilly: These 2 Stocks Have More Upside ↗
Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors. 
Via The Motley Fool
News headline image
Eli Lilly Now Has the World's Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy? ↗
Mounjaro generated $8.66 billion in sales in the first quarter. 
Via The Motley Fool
News headline image
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims ↗
The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits. 
Via MarketBeat
News headline image
My Top Obesity Stock to Buy and Hold ↗
Most weight-loss stocks are built on future expectations. Eli Lilly is built on current earnings and expanding demand. 
Via The Motley Fool
News headline image
Eli Lilly To Invest $4.5 Billion More In Indiana Manufacturing Sites ↗
Eli Lilly plans to invest $4.5 billion in Indiana, expanding its U.S. manufacturing footprint and supporting new weight-loss treatments. 
Via Benzinga
News headline image
ANI Pharmaceuticals (ANIP) Q1 Earnings: What To Expect
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Friday before market open. Here’s what you need to know. A... 
Via StockStory
Topics Artificial Intelligence
News headline image
Do Wall Street Analysts Like Eli Lilly Stock?
While Eli Lilly has slightly lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects. 
Via Barchart.com
Topics ETFs
News headline image
Elanco’s (NYSE:ELAN) Q1 CY2026 Sales Beat Estimates
Animal health company Elanco (NYSE:ELAN) announced better-than-expected revenue in Q1 CY2026, with sales up 14.9% year on year to $1.37 billion. The company ... 
Via StockStory
Topics Earnings
News headline image
Collegium Pharmaceutical (COLL) Q1 Earnings Report Preview: What To Look For
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before market open. Here’s what investors sho... 
Via StockStory
News headline image
Zoetis (ZTS) Q1 Earnings: What To Expect
Animal health company Zoetis (NYSE:ZTS) will be announcing earnings results this Thursday morning. Here’s what you need to know. Zoetis beat analysts’ revenu... 
Via StockStory
Topics Artificial Intelligence
News headline image
Amphastar Pharmaceuticals (AMPH) To Report Earnings Tomorrow: Here Is What To Expect
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be announcing earnings results this Thursday after market hours. Here’s what investors sho... 
Via StockStory
Topics Artificial Intelligence
News headline image
Earnings To Watch: Viatris (VTRS) Reports Q1 Results Tomorrow
Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before the bell. Here’s what investors should know. Viatris beat a... 
Via StockStory
Topics Artificial Intelligence
News headline image
Schrödinger (SDGR) Q1 2026 Earnings Transcript ↗
Schrödinger (SDGR) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidence ↗
Eli Lilly shares rise as Omvoh shows 4-year disease clearance in ulcerative colitis, with consistent safety and strong Crohn's data. 
Via Benzinga
News headline image
3 Quality Compounders to Own for Decades
Quality compounders are well-oiled machines. Their competitive advantages allow them to make profits consistently and reinvest them into projects that genera... 
Via StockStory
News headline image
Elanco (ELAN) Q1 Earnings: What To Expect
Animal health company Elanco (NYSE:ELAN) will be reporting results this Wednesday before the bell. Here’s what investors should know. Elanco beat analysts’ r... 
Via StockStory
Topics Artificial Intelligence
News headline image
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings this Wednesday before market hours. Here’s what investors should know. R... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons It's Not Too Late to Buy Eli Lilly Stock ↗
The company still has a strong lead in its core therapeutic area. 
Via The Motley Fool
News headline image
Is Eli Lilly Stock Heading for $1,000? ↗
Eli Lilly's valuation looks far more attractive now than it did even a year ago. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.